可切除和临界可切除胰腺导管腺癌（PDAC）的标准治疗已发展到手术切除前包括新辅助治疗。当前的指南要求在进行新辅助治疗之前通过超声内镜细针穿刺获得组织组织学诊断，这与鼓励推迟手术切除进行活检的指南不同。是否在活检确认恶性前继续治疗是一个复杂的决策，其中包括考虑追求和放弃活检时所涉及的身体和心理风险。在考虑成像和活检结果的准确性，有关临床体征/症状的贡献，以及在高度临床怀疑和主要手术切除等情况下是否可以放弃活检等现有的考虑活检的先例时。在考虑到道德医学实践（包括善行，不伤害，允许患者对自己的护理进行决策和功利主义）的方面时，分析指导PDAC切除和新辅助治疗中活检指南是否应继续有所差异是明智的。

The standard of care in resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC) has evolved to include neoadjuvant treatment before surgical resection. Current guidelines call for obtaining histologic tissue diagnosis via endoscopic ultrasound fine-needle aspiration before administration of neoadjuvant therapy, which differ from guidelines discouraging delay in surgical resection for a biopsy.Whether to proceed with treatment before a biopsy confirms that malignancy is a nuanced decision and includes considerations of physical and psychological risks entailed in both pursuing and forgoing a biopsy.Accuracy of imaging and biopsy results, the presence of contributing clinical signs/symptoms, and the existing precedents of considering biopsies as waivable such as in scenarios with high clinical suspicion and primary surgical resection.When considering the aspects of ethical medical practice including beneficence (doing good), nonmaleficence (avoiding harm), autonomy (allowing patients to make decisions about their care), and utilitarianism (doing the most good for the most people), analysis of whether guidelines guiding biopsies should continue to differ between resection and neoadjuvant treatments in PDAC is prudent.